Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma
@article{Kong2017EfficacyOP, title={Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma}, author={G. Kong and S. Grozinsky-Glasberg and M. Hofman and J. Callahan and A. Meirovitz and Ofra Maimon and D. Pattison and D. Gross and R. Hicks}, journal={The Journal of Clinical Endocrinology & Metabolism}, year={2017}, volume={102}, pages={3278–3287} }
Purpose: Treatment options for unresectable paraganglioma (PGL)/pheochromocytoma (PCC), especially with uncontrolled secondary hypertension (HTN), are limited. Preliminary studies with peptide receptor radionuclide therapy (PRRT) suggest efficacy, but data on HTN control and survival are lacking. We assessed PRRT outcomes in such patients from two referral centers. Methods: Twenty consecutive patients (13 men; age range, 21 to 77 years) with high somatostatin receptor (SSTR) expression treated… CONTINUE READING
Figures, Tables, and Topics from this paper
56 Citations
177Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma
- Medicine
- Endocrine connections
- 2020
- 1
- PDF
Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
- Medicine
- European journal of endocrinology
- 2019
- 5
- PDF
A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation
- Medicine
- Journal of clinical medicine
- 2019
- 4
- PDF
Somatostatin receptor targeted radioligand therapy in head and neck paraganglioma.
- Medicine
- World neurosurgery
- 2020
Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE
- Medicine
- Nuclear Medicine and Molecular Imaging
- 2019
- 3
Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management
- Medicine
- Current opinion in endocrinology, diabetes, and obesity
- 2019
- 9
Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma
- Medicine
- Neuroendocrinology
- 2019
- 25
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
- Medicine
- EJNMMI Research
- 2019
- 14
- Highly Influenced
131I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with 177Lu-DOTATATE peptide receptor radionuclide therapy
- Medicine
- Annals of Nuclear Medicine
- 2020
Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors
- Medicine
- The Journal of clinical endocrinology and metabolism
- 2019
- 21
- PDF
References
SHOWING 1-10 OF 33 REFERENCES
Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
- Medicine
- The Journal of clinical endocrinology and metabolism
- 2012
- 136
- PDF
Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
- Medicine
- The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
- 2008
- 96
Peptide receptor radionuclide therapy with 90Y/177Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)
- Medicine
- European Journal of Nuclear Medicine and Molecular Imaging
- 2015
- 40
Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy.
- Medicine
- The Journal of clinical endocrinology and metabolism
- 2009
- 58
- PDF
Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL).
- Medicine
- Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
- 2012
- 59
The Challenges of Treating Paraganglioma Patients with 177Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment Protocols
- Medicine
- Nuclear Medicine and Molecular Imaging
- 2015
- 15
Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors
- Medicine
- The New England journal of medicine
- 2017
- 962
- PDF
Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2009
- 145